The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.